FDA grants fast-track designation for CDI vaccine

SWIFTWATER, Pa. A vaccine for a bacterial infection that affects the gastrointestinal tract has been granted expedited approval by the Food and Drug Administration.

 

French drug maker Sanofi-Aventis announced Tuesday that it had received fast-track designation from the FDA for its investigational Clostridium difficile vaccine. The FDA grants the designation to ease the development of new drugs and vaccines for serious or life-threatening conditions or unmet medical needs.

 

 

C. difficile infection, or CDI, is one of the most common hospital-acquired infections in the developed world. The bacteria are present without causing symptoms in around 60% of infants and 3% of adults. Antibiotic treatments sometimes can disrupt the bacteria in the gut, causing C. difficile to multiply and release toxins that cause the symptoms associated with CDI.

 

Recommended stories

Login or Register to post a comment.